Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036341 (
schizophrenia
)
60,220
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Enzymes concerned with neurotransmitter metabolism were measured postmortem in 50 regions from the brains of 11 chronic schizophrenics, 2 patients with senile dementia, 1 depressive, and 18 controls. Enzymes studied were tyrosine hydroxylase, dopa decarboxylase, glutamic decarboxylase, choline acetyltransferase (CAT), and
acetylcholinesterase
. The schizophrenic group had high CAT activities in the hippocampus, caudate, putamen, and nucleus accumbens; the other patients from the same hospital did not. A compensatory response to long- or short-term drug usage is considered, but correlations are hard to establish in the group studied. An alternative hypothesis proposes that the high levels are a compensatory response to defective cholinergic receptors in the affected areas. On this hypothesis, and by analogy with chorea, dopaminergic antagonists would act in
schizophrenia
by helping to reestablish cholinergic-dopaminergic balance.
...
PMID:Possible changes in striatal and limbic cholinergic systems in schizophrenia. 4 82
Acetylcholinesterase
(
AChE
) was measured in the cerebrospinal fluid (CSF) of patients with a diagnosis of Huntington's disease, depression,
schizophrenia
, or mania and also in the CSF of normal subjects. No significant differences in CSF
AChE
were found between any diagnostic group and normal subjects. Furthermore, the administration of choline chloride, physostigmine, or probenecid did not significantly alter CSF
AChE
. No diurnal variation in CSF
AChE
activity was apparent. These findings, combined with the unclear relationship of brain
AChE
to CSF
AChE
, suggest that this measurement does not reflect the relative cholinergic underactivity presumed to exist in some neuropsychiatric conditions.
...
PMID:Cerebrospinal fluid acetylcholinesterase in neuropsychiatric disorders. 15 94
Acetyl- and butyryl-cholinesterase activities have been measured biochemically in normal brain tissue, in senile dementia of Alzheimer type and in mental disorders without Alzheimer-type abnormalities.
Acetylcholinesterase
was significantly reduced and butyrylcholinesterase significantly increased, compared with the normal, in the hippocampus and temporal cortex of the Alzheimer cases. No significant enzyme changes were seen in the other diseases investigated including multi-infarct dementia,
schizophrenia
and depression. There was no correlation between age and
acetylcholinesterase
activity, but a significant positive correlation between the butyrylcholinesterase activities with increasing age (60-90 years) was found in the hippocampus. The possible connection between cholinergic system pathology and these cholinesterase abnormalities in Alzheimer dementia is discussed.
...
PMID:Changes in brain cholinesterases in senile dementia of Alzheimer type. 70 27
The relation between electroencephalographic sleep parameters and plasma cholinesterase isozymes was examined in a group of 19 unmedicated schizophrenic patients. Rapid eye movement (REM) latency was found to be significantly inversely correlated with isozyme 3 (mainly
acetylcholinesterase
). The results are discussed in relation to cholinergic involvement in the regulation of REM sleep and in the pathophysiology of
schizophrenia
.
...
PMID:Plasma cholinesterase isozymes and REM latency in schizophrenia. 143 14
Twenty-three inpatients who met DSM-III criteria for
schizophrenia
were selected for cerebrospinal fluid (CSF) neurochemical study of tardive dyskinesia (TD). Ten inpatients had tardive dyskinesia, and the remaining 13 patients without TD served as controls. There were no intergroup differences in sex, age, duration of neuroleptic treatment, or in total amount of neuroleptics received between the TD and the control groups. Cerebrospinal fluid was collected by lumbar puncture, and concentrations of homovanillic acid (HVA), MHPG, 5-hydroxyindoleacetic acid (5-HIAA), and
acetylcholinesterase
(
AChE
) activity were measured. The concentrations of MHPG (TD 11.56 +/- 3.48 ng/ml versus control 14.20 +/- 3.86 ng/ml), 5-HIAA (45.27 +/- 9.77 ng/ml versus 40.34 +/- 13.77 ng/ml), and HVA (38.26 +/- 18.31 ng/ml versus 31.40 +/- 7.83 ng/ml), and the activity of
AChE
(TD 7.95 +/- 5.21 mmol/g.hr versus control 12.89 +/- 8.04 mmol/g.hr) showed no significant differences between the two groups, but the ratios of HVA/
AChE
(t = 2.21, p = 0.05), 5-HIAA/
AChE
(t = 2.62, p = 0.02), MHPG/HVA (t = -2.16, p = 0.04), and MHPG/5-HIAA (t = -2.48, p = 0.02) were statistically different. The results indicated that TD might involve an imbalance of dopamine-acetylcholine, noradrenalin-dopamine, noradrenalin-serotonin, and serotonin-acetylcholine.
...
PMID:CSF neurochemical study of tardive dyskinesia. 246 90
Choline acetyltransferase (ChAT) and
acetylcholinesterase
(
AChE
) were measured in anterior and posterior grey matter of the lumbar spinal cord and in temporal and frontal cortex from six cases of Alzheimer-type dementia (ATD), one case of Down's syndrome, three cases of
schizophrenia
(SZ) and six controls. Compared with control and SZ values, ChAT and
AChE
were reduced in ATD cerebral cortex. ChAT was reduced, and
AChE
unaltered, in ATD spinal cord. Decreased cord ChAT may be related to electrophysiological abnormalities which have been reported in motor nerves of patients with Alzheimer's disease.
...
PMID:Cholinergic enzymes in the spinal cord in Alzheimer-type dementia. 253 18
Evidence has accumulated to implicate neuropeptides localized within midbrain dopamine neurons (cholecystokinin, neurotensin,
acetylcholinesterase
) in synaptic transmission, mental disease, and pharmacotherapy. We suggest a means by which antipsychotic drugs alter the dynamics between dopamine and colocalized peptides: the intrinsic ability of these agents to stimulate dopamine neuronal activity while blocking dopamine receptors modulates the ratio of catecholaminergic to peptidergic transmission within the mesotelencephalic system. Imbalances of peptide and dopamine cotransmission and their modulation by neuroleptics may be relevant to the pathogenesis and pharmacotherapy of
schizophrenia
.
...
PMID:A mechanism for the involvement of colocalized neuropeptides in the actions of antipsychotic drugs. 256 35
Chemical and morphological changes in cholinergic marker enzymes,
acetylcholinesterase
(
AChE
), and choline acetyltransferase (ChAT) of striatum, hippocampus, and cerebral cortex were studied following haloperidol treatment of rats. After short-term (7-21 days) haloperidol treatment, the levels of both enzymes (
AChE
and ChAT) were increased in striatum and hippocampus (greater than 25%), but not in cortex. After long-term (+40 days) haloperidol treatment, the level of
AChE
activity returned to control levels in all brain areas, whereas the levels of striatal and hippocampal ChAT decreased by 26% and 29%, respectively. No change in levels of both enzymes was detected after acute treatment (single dose) of haloperidol or chronic treatment with either clozapine or imipramine. Morphological analysis of cholinergic neurons and their processes using monoclonal antibody to ChAT showed two types of changes following 40 days of haloperidol treatment. First, parallel to the observed decrease in the levels of ChAT activity there was a visual decrease in the immunoreactivity in neurons as well as in their processes in striatum and hippocampus. Second, there was an apparent reduction in the size and number of stained neurons and their processes. No changes were seen in immunoreactivity after an acute treatment with haloperidol. These results indicate that the chronic haloperidol treatment in rats causes changes in central cholinergic systems that may be relevant to the pathophysiology of
schizophrenia
and its treatment.
...
PMID:Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses. 329 56
Acetylcholinesterase
(
AChE
) from erythrocytes was solubilized by Triton X-100. Size and charge heterogeneity of
AChE
was investigated by polyacrylamide gel electrophoresis (PAGE) and isoelectric focusing (IEF) in polyacrylamide gels in the presence of 0.5% (v/v) Triton X-100. There were no interindividual differences in these parameters in 46 psychiatric patients (
schizophrenia
, major affective disorder, personality disorder, dependency, dementia) and controls. The specific activity of solubilized
AChE
did not discriminate between controls and patients or between the diagnostic subgroups.
...
PMID:Erythrocyte acetylcholinesterase in psychiatric disorders and controls. 365 30
Cholinergic processes were measured in plasma and red blood cells (RBC) obtained from patients with mania, depression, and
schizophrenia
. RBC choline levels were elevated in manic patients, and lithium treatment led to a further increase. RBC choline transport was below normal in manic patients, and lithium treatment further reduced choline transport in addition to reducing the apparent affinity for choline. RBC
acetylcholinesterase
was low in depressed and schizophrenic patients, but not in manic patients, whereas plasma
acetylcholinesterase
was reduced only in depressed patients. Plasma nonspecific cholinesterase was below normal in all groups of patients. These results indicate unique patterns of differences from controls in the cholinergic system in blood samples from patients with different psychiatric illnesses.
...
PMID:Cholinergic processes in blood samples from patients with major psychiatric disorders. 406 16
1
2
3
4
5
6
7
8
9
10
Next >>